CIK 0001582313
- Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- EIN
- 980661854
- Phone
- +1 604-484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-12 | COHEN CHARLES J. VP, Biology | Exercise or conversion · Stock Option (Right to Buy) | −26,748 | 0 | ||
| 2017-11-15 | AZAB MOHAMMAD Director | Purchase | +15,000 | $2.22 | $33K | 44,210 |
| 2017-10-23 | MORTIMER IAN CFO & COO | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2017-10-23 | ROBIN SHERRINGTON SVP Bus. & Corp. Development | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2017-10-23 | PIMSTONE SIMON N. President & CEO | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2017-10-23 | GOLDBERG Y. PAUL SVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2017-10-23 | EMPFIELD JAMES R. SVP, Drug Discovery | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2017-10-23 | COHEN CHARLES J. VP, Biology | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2017-09-22 | AZAB MOHAMMAD Director | Purchase | +8,000 | $2.95 | $24K | 29,210 |
| 2017-09-21 | AZAB MOHAMMAD Director | Purchase | +2,000 | $2.95 | $6K | 21,210 |
| 2017-08-18 | AZAB MOHAMMAD Director | Purchase | +6,312 | $2.90 | $18K | 19,210 |
| 2017-08-18 | WINQUIST RAYMOND Head, Translational Research | Purchase | +1,000 | $3.00 | $3K | 1,000 |
| 2017-08-17 | AZAB MOHAMMAD Director | Purchase | +23 | $2.65 | $61 | 12,898 |
| 2017-08-15 | EMPFIELD JAMES R. SVP, Drug Discovery | Purchase | +10,000 | $2.48 | $25K | 10,000 |
| 2017-08-15 | BVF PARTNERS L P/IL 10% owner | Purchase | +11,429 | $2.41 | $28K | 1,674,468 |
| 2017-08-15 | BVF PARTNERS L P/IL 10% owner | Purchase | +7,429 | $2.41 | $18K | 1,077,694 |
| 2017-08-14 | BVF PARTNERS L P/IL 10% owner | Purchase | +28,007 | $2.70 | $76K | 1,663,039 |
| 2017-08-14 | BVF PARTNERS L P/IL 10% owner | Purchase | +13,337 | $2.70 | $36K | 1,070,265 |
| 2017-08-14 | Svoronos Dawn Director | Purchase | +50,000 | $2.82 | $141K | 50,000 |
| 2017-08-14 | Hayden Michael R Director | Purchase | +15,000 | $2.75 | $41K | 161,187 |
Page 29 of 42 · 836 trades